The BTIG Research Begins Coverage on Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)

Xavier Trudeau
Juillet 17, 2017

Oppenheimer Holdings, Inc. set a $34.00 price target on shares of Eiger BioPharmaceuticals and gave the stock a "buy" rating in a research note on Wednesday, May 10th. Piper Jaffray initiated the stock with "Overweight" rating in Monday, October 31 report.

Several other research analysts also recently commented on the company. Jefferies Group LLC reiterated a "buy" rating and issued a $43.00 target price on shares of Alder BioPharmaceuticals in a research note on Thursday, March 30th.

Shares of Eiger BioPharmaceuticals (NASDAQ EIGR) opened at 9.25 on Wednesday. The stock has a consensus rating of "Buy" and a consensus target price of $35.00. Aegis restated a "buy" rating and set a $41.00 price objective on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 5th. Needham & Company LLC started coverage on Alder BioPharmaceuticals in a report on Monday, May 15th. They issued a buy rating and a $36.00 price target for the company. Also, there are 1 buy, 0 sell and 1 strong sell ratings, collectively assigning a 1.63 average brokerage recommendation. Alder BioPharmaceuticals now has a consensus rating of Buy and a consensus price target of $35.00. A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range. The firm's market capitalization is $587.28 million. The share last price represents downtick move of -55.16% in value from company's 52-Week high price and shows 51.64% above change in value from its 52-Week low price.

Wall Street await Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to release earnings on July, 25. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.35) by $0.01. During the same period in the previous year, the company posted ($0.76) earnings per share. After having $-1.99 EPS previously, Alder Biopharmaceuticals Inc's analysts see -14.07% EPS growth.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of US and worldwide copyright & trademark law. The legal version of this piece of content can be accessed at State Street Corp now owns 1,758,687 shares of the biopharmaceutical company's stock worth $36,579,000 after buying an additional 268,187 shares during the period. The Cypress Capital Group holds 33,690 shares with $3.90M value, down from 36,623 last quarter. Credit Suisse AG now owns 243,807 shares of the biopharmaceutical company's stock worth $5,071,000 after buying an additional 40,260 shares during the period. Janus Capital Management LLC raised its position in shares of Alder BioPharmaceuticals by 4.7% in the first quarter. Marshall Wace North America L.P. acquired a new position in Alder BioPharmaceuticals during the first quarter worth approximately $4,450,000. Redmile Group LLC increased its stake in shares of Alder BioPharmaceuticals by 107.5% in the first quarter.

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical firm that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.

D'autres rapports CampDesrEcrues

Discuter de cet article